c-erbB-2 Oncoprotein and Breast Cancer Survival
Author Information
Author(s): C Charpin, S Garcia, C Bouvier, F Martini, M-N Lavaut, C Allasia, P Bonnier, L Andrac
Primary Institution: Department of Pathology, EA 875 'Oncogenese des tumeurs solides', Faculté de Médecine, Marseilles, France
Hypothesis
The study investigates the prognostic significance of c-erbB-2 oncoprotein overexpression in breast carcinomas.
Conclusion
c-erbB-2 expression is a significant prognostic indicator for overall and disease-free survival in breast cancer patients.
Supporting Evidence
- Patients with c-erbB-2 positive surfaces greater than 35% had poorer overall survival.
- Marked c-erbB-2 expression correlated with shorter disease-free survival in node-positive patients.
- Immunocytochemical assays were performed under optimal technical conditions.
Takeaway
This study found that higher levels of a protein called c-erbB-2 in breast cancer can mean patients might not live as long or have more problems after treatment.
Methodology
Automated immunocytochemical assays were performed on frozen tissue sections to evaluate c-erbB-2 expression.
Limitations
The study may have limitations due to variations in technical procedures and the lack of standardized evaluation methods.
Participant Demographics
Patients aged 34 to 79 years, with a mean age of 53.2 years.
Statistical Information
P-Value
P = 0.045 for overall survival in N- patients; P = 0.015 for overall survival in N+ patients; P = 0.005 for disease-free survival in N+ patients.
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website